精准医学在风湿病学中的前景
系统性自身免疫性风湿病(SARD)在临床表现、病程和治療反應上異質性很大,精準醫學旨在根據個體患者特定時間的致病機制定制治療,被視為SARD臨床治療的「聖杯」。本文綜述當前以達標治療和自身抗體檢測進行患者分層的策略及其不足,並討論高通量組學技術在多重層面全面分析、識別可減停潛在毒性藥物或更好響應分子靶向治療的患者亞組方面的進展,以及臨床轉化面臨的挑戰與未來方向。
要点
- SARD在臨床表現、病程和治療反應上異質性大,精準醫學是SARD臨床治療的目標。
- 當前達標治療與自身抗體檢測分層策略遠非最優。
- 高通量組學全面分析有助識別可減停毒性藥物或更好響應靶向治療的亞組。
核心结论
- 精準醫學有望優化SARD結局並識別新的治療通路,但臨床轉化之路仍面臨諸多挑戰。
研究设计与样本
- 本文為綜述,討論跨多種SARD解析細胞與分子異質性的近期工作及臨床實施分層策略的未來方向。
主要发现
- 高通量組學技術使多層面全面分析成為可能,有助識別可能減停潛在毒性藥物或更好響應當前分子靶向治療的患者亞組。
局限性
- 原文指出在通往臨床轉化的道路上仍有許多挑戰。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic autoimmune rheumatic diseases (SARDs) exhibit extensive heterogeneity in clinical presentation, disease course, and treatment response. Therefore, precision medicine - whereby treatment is tailored according to the underlying pathogenic mechanisms of an individual patient at a specific time - represents the 'holy grail' in SARD clinical care. Current strategies include treat-to-target therapies and autoantibody testing for patient stratification; however, these are far from optimal. Recent innovations in high-throughput 'omic' technologies are now enabling comprehensive profiling at multiple levels, helping to identify subgroups of patients who may taper off potentially toxic medications or better respond to current molecular targeted therapies. Such advances may help to optimize outcomes and identify new pathways for treatment, but there are many challenges along the path towards clinical translation. In this Review, we discuss recent efforts to dissect cellular and molecular heterogeneity across multiple SARDs and future directions for implementing stratification approaches for SARD treatment in the clinic.
引用
- Guthridge JM, Wagner CA, James JA, et al. The promise of precision medicine in rheumatology. Nat Med. 2022. PMID: 35788174. doi:10.1038/s41591-022-01880-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。